43083-14-3

Basic information

• Product Name: 2-Chloro-6-phenylnicotinonitrile
• Synonyms: 2-Chloro-6-phenylnicotinonitrile;2-chloro-6-phenylpyridine-3-carbonitrile;2-Chloro-6-phenylpyridine-3-carbonitrile, 2-Chloro-3-cyano-6-phenylpyridine
• CAS NO: 43083-14-3
• Molecular Formula: C₁₂H₇ClN₂
• Molecular Weight: 214.65
• EINECS: 201-525-2
• Product Categories: Pyridines
• Mol File: 43083-14-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 155-159°C
• Boiling Point: 376.4 °C at 760mmHg
• Flash Point: 181.4 °C
• Appearance: /
• Density: 1.3 g/cm³
• Vapor Pressure: 3.3E-06mmHg at 25°C
• Refractive Index: 1.632
• PKA: -3.62±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-6-phenylnicotinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-phenylnicotinonitrile(43083-14-3)
• EPA Substance Registry System: 2-Chloro-6-phenylnicotinonitrile(43083-14-3)

Safety Data

• Hazard Codes: T
• HazardClass: IRRITANT
• Hazardous Substances Data: 43083-14-3(Hazardous Substances Data)

Usage

General Description

2-Chloro-6-phenylnicotinonitrile is a chemical compound with the molecular formula C12H8ClN2. It is a synthetic intermediate used in the production of pharmaceuticals, agrochemicals, and other specialty chemicals. 2-Chloro-6-phenylnicotinonitrile is commonly utilized in the synthesis of various bioactive molecules, including antiviral, antifungal, and antimicrobial agents. It is also used in the development of new materials and has potential applications in medicinal chemistry. 2-Chloro-6-phenylnicotinonitrile is a solid, white to light yellow in color, and is mainly produced through chemical synthesis procedures. It is important to handle this compound with caution, as it may pose certain health and environmental hazards.

InChI:InChI=1/C12H7ClN2/c13-12-11(8-14)10(6-7-15-12)9-4-2-1-3-5-9/h1-7H

Upstream product

• 43083-13-2 3-cyano-2-hydroxy-6-phenylpyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 98-86-2 acetophenone 
• 109-77-3 malononitrile 
• 108-86-1 bromobenzene 
• 24388-23-6 2-phenyl-4,4,5,5-tetramethyl-1,3,2-dioxoborole 
• 40381-90-6 2,6-dichloro-3-pyridinecarbonitrile 
• 69750-00-1 2-chloro-6-phenyl-nicotinamide 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 98-80-6 phenylboronic acid 
• 43083-13-2 1,2-dihydro-2-oxo-6-phenylpyridine-3-carbonitrile 

Downstream Products

• 1235487-56-5 C₁₇H₁₇N₃ 
• 92126-72-2 6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile 
• 139326-10-6 3-Amino-6-phenyl-thieno<2,3-b>pyridin-2-carbonitril 
• 296797-34-7 methyl 3-amino-6-phenylthieno[2,3-b]pyridine-2-carboxylate 
• 1013647-71-6 2-(2-chlorophenoxy)-6-phenylnicotinonitrile 
• 69750-01-2 2-chloro-6-phenylpyridine-3-carboxylic acid 

Relevant articles and documents

Discovery and optimization of thienopyridine derivatives as novel urea transporter inhibitors

Urea transporters (UTs) play an important role in the urine concentrating mechanism and are recognized as novel targets for developing small molecule inhibitors with salt-sparing diuretic activity. Thienoquinoline derivatives, a class of novel UT-B inhibitors identified by our group, play a significant diuresis in animal model. However, the poor solubility and low bioavailability limited its further development. To overcome these shortcomings, the structure modification of thienoquinoline was carried out in this study, which led to the discovery of novel thienopyridine derivatives as specific urea transporter inhibitors. Further optimization obtained the promising preclinical candidate 8n with not only excellent inhibition effect on urea transporters and diuretic activity on rat model, but also suitable water solubility and Log P value.

PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain fused triaryl amine compounds of the following formula (for convenience, collectively referred to herein as "FTA compounds"), which, inter alia, inhibit LIM kinase (LIMK) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit LIMK activity, and in the treatment of diseases and conditions that are mediated by LIMK, that are ameliorated by the inhibition of LIMK activity, etc., including proliferative conditions such as cancer (e.g., breast cancer, prostate cancer, melanoma, glioma, etc.), as well as vasodilation (including, e.g., hypertension, angina, cerebral vasospasm, and ischemia following subarachnoid hemorrhage), neurodegenerative disorders, atherosclerosis, fibrosis, and inflammatory diseases (including, e.g., Crohn's disease and chronic obstructive pulmonary disease (COPD)), and glaucoma (also known as ocular hypertension).

A facile method for the synthesis of nicotinonitriles from ketones via a one-pot chloromethyleneiminium salt mediated three-component reaction

Simple enolizable ketones such as acetophenones and benzalacetones were treated with malononitrile under Vilsmeier-Haack reaction conditions to afford 2-chloronicotinonitriles. The reaction proceeds via a one-pot chloromethyleneiminium salt mediated three